PALI

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Palisade Bio Inc

NASDAQ | PALI

0.89

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$7.20M

Market Cap

-

P/E Ratio

-3.64

EPS

$4.31

52 Week High

$0.53

52 Week Low

HEALTHCARE

Sector

PALI Chart

Recent Chart
Price Action

PALI Technicals

Tags:

PALI Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$3K
Total Revenue $0
Cost Of Revenue $3K
Costof Goods And Services Sold $3K
Operating Income -$15M
Selling General And Administrative $5.8M
Research And Development $9.1M
Operating Expenses $15M
Investment Income Net -
Net Interest Income -$12K
Interest Income -
Interest Expense $12K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$409K
Income Before Tax -$14M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$14M
Comprehensive Income Net Of Tax -
Ebit -$14M
Ebitda -$15M
Net Income -$14M

Revenue & Profitability

Earnings Performance

PALI Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $11M
Total Current Assets $10M
Cash And Cash Equivalents At Carrying Value $9.8M
Cash And Short Term Investments $9.8M
Inventory $12K
Current Net Receivables $24K
Total Non Current Assets $386K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $649K
Other Non Current Assets -
Total Liabilities $3.4M
Total Current Liabilities $3.2M
Current Accounts Payable $1.1M
Deferred Revenue -
Current Debt -
Short Term Debt $169K
Total Non Current Liabilities $152K
Capital Lease Obligations $90K
Long Term Debt -
Current Long Term Debt $79K
Long Term Debt Noncurrent -
Short Long Term Debt Total $169K
Other Current Liabilities $2M
Other Non Current Liabilities $150K
Total Shareholder Equity $7.5M
Treasury Stock -
Retained Earnings -$136M
Common Stock $27K
Common Stock Shares Outstanding $1.4M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$12M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $3K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $9.6M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $11K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$14M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$3K
Total Revenue $0
Cost Of Revenue $3K
Costof Goods And Services Sold $3K
Operating Income -$15M
Selling General And Administrative $5.8M
Research And Development $9.1M
Operating Expenses $15M
Investment Income Net -
Net Interest Income -$12K
Interest Income -
Interest Expense $12K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$409K
Income Before Tax -$14M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$14M
Comprehensive Income Net Of Tax -
Ebit -$14M
Ebitda -$15M
Net Income -$14M

PALI News

PALI Profile

Palisade Bio Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Palisade Bio Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies that enhance human health by protecting the gastrointestinal mucosal barrier. Based in Carlsbad, California, the company is dedicated to addressing unmet medical needs through its proprietary drug candidates that aim to improve outcomes in patients with gastrointestinal disorders. With a strong emphasis on research and development, Palisade Bio is poised to make significant contributions to the field of gastrointestinal health and therapeutics.

DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
YAAS
-31.07%
$0.06
NEHC
+33.33%
$1.84
NUAI
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.14%
$2.77
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BITF
-5.22%
$2.54
BBD
+0.91%
$3.30
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.16%
$35.75
BURU
-10.14%
$0.12
BMNR
+1.87%
$50.50
IXHL
-0.01%
$0.59
RMBL
+60.50%
$3.21
RXRX
+1.94%
$4.72
ETHD
-5.95%
$3.95
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RAYA
-3.15%
$0.04
RR
+2.68%
$4.20
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
CLSK
-5.26%
$12.96
SRM
+53.27%
$10.30
PFE
+0.67%
$23.76
ACHR
-0.53%
$9.27
IONQ
-3.09%
$67.28
BB
+6.66%
$4.96
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.43%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.43%
$58.40
AQMS
+48.37%
$7.30
ABEV
0.00%
$2.29
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83
DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
YAAS
-31.07%
$0.06
NEHC
+33.33%
$1.84
NUAI
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.14%
$2.77
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BITF
-5.22%
$2.54
BBD
+0.91%
$3.30
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.16%
$35.75
BURU
-10.14%
$0.12
BMNR
+1.87%
$50.50
IXHL
-0.01%
$0.59
RMBL
+60.50%
$3.21
RXRX
+1.94%
$4.72
ETHD
-5.95%
$3.95
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RAYA
-3.15%
$0.04
RR
+2.68%
$4.20
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
CLSK
-5.26%
$12.96
SRM
+53.27%
$10.30
PFE
+0.67%
$23.76
ACHR
-0.53%
$9.27
IONQ
-3.09%
$67.28
BB
+6.66%
$4.96
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.43%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.43%
$58.40
AQMS
+48.37%
$7.30
ABEV
0.00%
$2.29
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.